Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Woon-Seob | - |
dc.contributor.author | Oh, Sangtae | - |
dc.contributor.author | An, Sung-Wan | - |
dc.contributor.author | Park, Gab-Man | - |
dc.contributor.author | Kwon, Daeho | - |
dc.contributor.author | Ham, Jungyeob | - |
dc.contributor.author | Lee, Seokjoon | - |
dc.contributor.author | Park, Byong-Gon | - |
dc.date.accessioned | 2024-01-20T12:33:26Z | - |
dc.date.available | 2024-01-20T12:33:26Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2013-04 | - |
dc.identifier.issn | 1537-1891 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/128198 | - |
dc.description.abstract | A specific blocker of L-type Ca2+ channels may be useful in decreasing arterial tone by reducing the open-state probability of L-type Ca2+ channels. The aim of the present study was to evaluate the farnesylacetones, which are major active constituents of Sargassum siliquastrum, regarding their vasodilatation efficacies, selectivities toward L-type Ca2+ channels, and in vivo antihypertensive activities. The application of 5E-(famesylacetone 311) or 5Z-farnesylacetone (farnesylacetone 312) induced concentration-dependent vasodilatation effects on the basilar artery that was pre-contracted with depolarization and showed an ignorable potential role of endothelial-derived nitric oxide. We also tested farnesylacetone 311 or 312 to determine their pharmacological profiles for the blockade of native L-type Ca2+ channels in basilar arterial smooth muscle cells (BASMCs) and ventricular myocytes (VMCs), cloned L-(alpha 1C/beta 2a/alpha 2 delta), N-(alpha 1B/beta 1b/alpha 2 delta), and T-type Ca2+ channels (alpha 1G, alpha 1H, and alpha 1I). Farnesylacetone 311 or 312 showed greater selectivity toward the L-type Ca2+ channels among the tested voltage-gated Ca2+ channels. The ranked order of the potency for farnesylacetone 311 was cloned alpha 1C L-type (BASMC) L-type (VMCs)>alpha 1B>alpha 1H>alpha 1I>alpha 1G and that for famesylacetone 312 was cloned alpha 1C L-type (BASMCs) L-type (VMCs)>alpha 1H>alpha 1G>alpha 1B>alpha 1I. The oral administration of the famesylacetone 311 (80 mg/kg) conferred potent, long-lasting antihypertensive activity in spontaneous hypertensive rats, but it did not alter the heart rate. (C) 2013 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | SPONTANEOUSLY HYPERTENSIVE-RATS | - |
dc.subject | HIGH BLOOD-PRESSURE | - |
dc.subject | SMOOTH-MUSCLE-CELLS | - |
dc.subject | GATED ION CHANNELS | - |
dc.subject | RESISTANCE ARTERIES | - |
dc.subject | SYMPATHETIC NEURONS | - |
dc.subject | CA2+ CHANNELS | - |
dc.subject | WISTAR-KYOTO | - |
dc.subject | PHARMACOLOGY | - |
dc.subject | DEPOLARIZATION | - |
dc.title | 5E- and 5Z-farnesylacetones from Sargassum siliquastrum as novel selective L-type calcium channel blockers | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.vph.2013.02.001 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | VASCULAR PHARMACOLOGY, v.58, no.4, pp.299 - 306 | - |
dc.citation.title | VASCULAR PHARMACOLOGY | - |
dc.citation.volume | 58 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 299 | - |
dc.citation.endPage | 306 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000317166700007 | - |
dc.identifier.scopusid | 2-s2.0-84875368253 | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | SPONTANEOUSLY HYPERTENSIVE-RATS | - |
dc.subject.keywordPlus | HIGH BLOOD-PRESSURE | - |
dc.subject.keywordPlus | SMOOTH-MUSCLE-CELLS | - |
dc.subject.keywordPlus | GATED ION CHANNELS | - |
dc.subject.keywordPlus | RESISTANCE ARTERIES | - |
dc.subject.keywordPlus | SYMPATHETIC NEURONS | - |
dc.subject.keywordPlus | CA2+ CHANNELS | - |
dc.subject.keywordPlus | WISTAR-KYOTO | - |
dc.subject.keywordPlus | PHARMACOLOGY | - |
dc.subject.keywordPlus | DEPOLARIZATION | - |
dc.subject.keywordAuthor | Farnesylacetones | - |
dc.subject.keywordAuthor | L-type calcium channel | - |
dc.subject.keywordAuthor | Vasodilatation | - |
dc.subject.keywordAuthor | Hypertension | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.